9-Jun-2026
Sutro Biopharma Shareholders Back Board, Pay and Auditor
TipRanks (Mon, 8-Jun 5:25 PM ET)
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
Globe Newswire (Thu, 14-May 4:05 PM ET)
Globe Newswire (Sun, 19-Apr 7:45 PM ET)
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
Globe Newswire (Mon, 23-Mar 4:05 PM ET)
Market Chameleon (Tue, 10-Feb 4:41 AM ET)
Sutro Biopharma Advances STRO-004 with First Patients Dosed in Pioneering Phase 1 Study
Market Chameleon (Thu, 4-Dec 5:03 AM ET)
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Sutro Biopharma trades on the NASDAQ stock market under the symbol STRO.
As of June 9, 2026, STRO stock price climbed to $25.79 with 152,618 million shares trading.
STRO has a beta of 1.91, meaning it tends to be more sensitive to market movements. STRO has a correlation of 0.07 to the broad based SPY ETF.
STRO has a market cap of $427.27 million. This is considered a Small Cap stock.
Last quarter Sutro Biopharma reported $15 million in Revenue and -$2.94 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.10.
In the last 3 years, STRO traded as high as $61.30 and as low as $5.23.
The top ETF exchange traded funds that STRO belongs to (by Net Assets): VTI, VXF, IWC, PRFZ, WCEO.
STRO has outperformed the market in the last year with a return of +212.0%, while the SPY ETF gained +24.1%. However, in the most recent history, STRO shares have underperformed the stock market with its stock returning +3.2% in the last 3 month period and -5.8% for the last 2 week period, while SPY has returned +8.9% and -1.8%, respectively.
STRO support price is $23.44 and resistance is $27.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STRO shares will trade within this expected range on the day.
